National Survey on GERD Patients (Adults and Children) (RGO à trav)
This study has been completed.
Sponsor:
AstraZeneca
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00833573
First received: January 30, 2009
Last updated: November 13, 2009
Last verified: November 2009
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | January 30, 2009 | ||||
| Last Updated Date | November 13, 2009 | ||||
| Start Date ICMJE | January 2009 | ||||
| Primary Completion Date | Not Provided | ||||
| Current Primary Outcome Measures ICMJE |
To describe GERD digestive expression according to ages: - children (from 0-23 months) and (24 months and more)- adults (from 18-29 years old), (from 30-39 years old), (from 40-49 years old), (from 50-59 years old), (more than 60 years old) [ Time Frame: once ] [ Designated as safety issue: No ] | ||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||
| Change History | Complete list of historical versions of study NCT00833573 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE | Not Provided | ||||
| Original Secondary Outcome Measures ICMJE | Not Provided | ||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | National Survey on GERD Patients (Adults and Children) | ||||
| Official Title ICMJE | National Survey on GERD Patients (Adults and Children) | ||||
| Brief Summary | To describe GERD digestive expression according to ages: - children (from 0 to 23 months) and (24 months and more)- adults (from 18 to 29 years old), (from 30 to 39 years old), (from 40 to 49 years old), (from 50 to 59 years old), (more than 60 years old) |
||||
| Detailed Description | Not Provided | ||||
| Study Type ICMJE | Observational | ||||
| Study Design ICMJE | Observational Model: Cohort Time Perspective: Cross-Sectional |
||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Not Provided | ||||
| Sampling Method | Probability Sample | ||||
| Study Population | For GP : the first 3 consecutive adult patients and the first children seen during the GP's visit with a diagnosis of GERD.For Paediatrics : the first 2 consecutive children seen during the Paediatric's visit with a diagnosis of GERD. |
||||
| Condition ICMJE | GERD (Gastroesophageal Reflux Disease) | ||||
| Intervention ICMJE | Not Provided | ||||
| Study Group/Cohort (s) |
|
||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Completed | ||||
| Estimated Enrollment ICMJE | 4400 | ||||
| Completion Date | October 2009 | ||||
| Primary Completion Date | Not Provided | ||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria: - |
||||
| Gender | Both | ||||
| Ages | Not Provided | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
| Location Countries ICMJE | France | ||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT00833573 | ||||
| Other Study ID Numbers ICMJE | NIS-GFR-DUM-2008/2 | ||||
| Has Data Monitoring Committee | No | ||||
| Responsible Party | Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals | ||||
| Study Sponsor ICMJE | AstraZeneca | ||||
| Collaborators ICMJE | Not Provided | ||||
| Investigators ICMJE |
|
||||
| Information Provided By | AstraZeneca | ||||
| Verification Date | November 2009 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||